Share-based Payment Arrangement, Expense in USD of REGENXBIO Inc. from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
REGENXBIO Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2014 to Q3 2025.
  • REGENXBIO Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9M, a 8.96% decline year-over-year.
  • REGENXBIO Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $35.7M, a 4.1% decline year-over-year.
  • REGENXBIO Inc. annual Share-based Payment Arrangement, Expense for 2024 was $38.5M, a 4.48% decline from 2023.
  • REGENXBIO Inc. annual Share-based Payment Arrangement, Expense for 2023 was $40.3M, a 1.28% decline from 2022.
  • REGENXBIO Inc. annual Share-based Payment Arrangement, Expense for 2022 was $40.8M, a 5.1% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

REGENXBIO Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $35.7M $9M -$886K -8.96% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 $36.6M $8.65M -$782K -8.29% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $37.4M $8.54M -$1.07M -11.1% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 $38.5M $9.54M +$1.2M +14.4% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025
Q3 2024 $37.3M $9.88M -$335K -3.28% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 $37.6M $9.44M -$1.07M -10.2% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 $38.7M $9.6M -$1.6M -14.3% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 $40.3M $8.34M -$1.07M -11.4% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025
Q3 2023 $41.3M $10.2M -$26K -0.25% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 $41.4M $10.5M +$169K +1.64% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024
Q1 2023 $41.2M $11.2M +$406K +3.76% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 $40.8M $9.41M +$246K +2.69% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025
Q3 2022 $40.5M $10.2M +$511K +5.25% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 $40M $10.3M +$343K +3.43% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023
Q1 2022 $39.7M $10.8M +$880K +8.87% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023
Q4 2021 $38.8M $9.16M +$1.58M +20.9% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024
Q3 2021 $37.2M $9.73M +$1.7M +21.1% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 $35.5M $9.99M +$1.68M +20.2% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022
Q1 2021 $33.9M $9.92M +$1.9M +23.7% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022
Q4 2020 $31.9M $7.58M +$706K +10.3% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023
Q3 2020 $31.2M $8.04M +$873K +12.2% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021
Q2 2020 $30.4M $8.32M +$1.22M +17.1% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 $29.2M $8.02M +$2.3M +40.2% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q4 2019 $26.9M $6.88M +$1.99M +40.7% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022
Q3 2019 $24.9M $7.16M +$2.68M +59.8% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020
Q2 2019 $22.2M $7.1M +$3.12M +78.3% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 $19.1M $5.72M +$2.43M +73.7% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 $16.6M $4.89M +$2.09M +74.7% 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021
Q3 2018 $14.6M $4.48M +$1.75M +64% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019
Q2 2018 $12.8M $3.98M +$1.5M +60.4% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019
Q1 2018 $11.3M $3.29M +$700K +27% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019
Q4 2017 $10.6M $2.8M +$797K +39.9% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2020
Q3 2017 $9.81M $2.73M +$905K +49.5% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018
Q2 2017 $8.9M $2.48M +$827K +49.9% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018
Q1 2017 $8.08M $2.59M +$1.05M +67.6% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018
Q4 2016 $7.03M $2M 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019
Q3 2016 $1.83M +$480K +35.6% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017
Q2 2016 $1.66M 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017
Q1 2016 $1.55M 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017
Q3 2015 $1.35M 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016

REGENXBIO Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $38.5M -$1.8M -4.48% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025
2023 $40.3M -$521K -1.28% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025
2022 $40.8M +$1.98M +5.1% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025
2021 $38.8M +$6.86M +21.5% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024
2020 $31.9M +$5.1M +19% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023
2019 $26.9M +$10.2M +61.4% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 $16.6M +$6.04M +56.9% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021
2017 $10.6M +$3.57M +50.8% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020
2016 $7.03M +$4.11M +141% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019
2015 $2.92M +$2.6M +816% 01 Jan 2015 31 Dec 2015 10-K 06 Mar 2018
2014 $319K 01 Jan 2014 31 Dec 2014 10-K 07 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.